I'm a partner in http://kratom.in.net/ kratom drug Amgen, whose preliminary offer of $120 per share wasrejected by Onyx's board in late June and led to an auction ofthe company, is still keen to buy Onyx and appears to be themore likely buyer, the people said this week.